Working… Menu

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03900442
Recruitment Status : Recruiting
First Posted : April 3, 2019
Last Update Posted : September 22, 2021
Information provided by (Responsible Party):
Prescient Therapeutics, Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2023
Estimated Study Completion Date : April 30, 2023